AAPL347.68-0.55 (-0.16%) ▼|ABBV285.80+0.61 (+0.21%) ▲|ABT103.39+0.88 (+0.85%) ▲|ACN246.85-11.89 (-4.60%) ▼|ADBE265.46-5.09 (-1.88%) ▼|AMAT379.68+4.10 (+1.09%) ▲|AMD517.55+9.62 (+1.89%) ▲|AMGN440.79-6.50 (-1.45%) ▼|AMT188.31+6.74 (+3.71%) ▲|AMZN248.72-1.66 (-0.66%) ▼|AVGO324.44+1.20 (+0.37%) ▲|AXP313.19-11.99 (-3.69%) ▼|BA188.39+0.84 (+0.45%) ▲|BAC50.69-0.39 (-0.76%) ▼|BKNG157.14-3.96 (-2.46%) ▼|BLK1,113.83-23.46 (-2.06%) ▼|BMY61.60-1.41 (-2.23%) ▼|BNY145.18-0.14 (-0.10%) ▼|BRK-B541.26-5.72 (-1.04%) ▼|C120.98-1.53 (-1.25%) ▼|CAT687.03-17.02 (-2.42%) ▼|CL93.96-3.44 (-3.53%) ▼|CMCSA22.79-0.06 (-0.24%) ▼|COF200.41-3.03 (-1.49%) ▼|COP151.55+5.92 (+4.06%) ▲|COST1,005.69-12.53 (-1.23%) ▼|CRM248.53-1.76 (-0.70%) ▼|CSCO106.27+1.38 (+1.31%) ▲|CVS93.49-0.99 (-1.05%) ▼|CVX232.73+6.05 (+2.67%) ▲|DE644.45+0.83 (+0.13%) ▲|DHR227.11-2.64 (-1.15%) ▼|DIS112.83-0.30 (-0.27%) ▼|DUK124.62-0.78 (-0.62%) ▼|EMR162.15+1.86 (+1.16%) ▲|FDX299.08-4.84 (-1.59%) ▼|GD350.40-0.39 (-0.11%) ▼|GE287.94-5.60 (-1.91%) ▼|GEV825.89-1.53 (-0.18%) ▼|GILD156.61-0.58 (-0.37%) ▼|GM75.84-1.38 (-1.78%) ▼|GOOG319.00-1.76 (-0.55%) ▼|GOOGL322.04-2.18 (-0.67%) ▼|GS882.67-8.63 (-0.97%) ▼|HD318.43-9.30 (-2.84%) ▼|HON221.41+3.10 (+1.42%) ▲|IBM252.93+0.82 (+0.33%) ▲|INTC86.84+1.35 (+1.57%) ▲|INTU346.15-8.75 (-2.47%) ▼|ISRG453.48+9.63 (+2.17%) ▲|JNJ263.03-4.59 (-1.71%) ▼|JPM332.14-4.41 (-1.31%) ▼|KO92.81-2.54 (-2.66%) ▼|LIN508.28-2.08 (-0.41%) ▼|LLY1,264.74-41.96 (-3.21%) ▼|LMT606.54+16.63 (+2.82%) ▲|LOW198.74-5.63 (-2.75%) ▼|LRCX230.80+0.65 (+0.28%) ▲|MA622.06-11.15 (-1.76%) ▼|MCD247.61-5.02 (-1.99%) ▼|MDLZ63.54-1.65 (-2.53%) ▼|MDT95.87-0.72 (-0.75%) ▼|META644.58-4.28 (-0.66%) ▼|MMM173.96-1.61 (-0.91%) ▼|MO74.46-1.61 (-2.12%) ▼|MRK145.00-2.24 (-1.52%) ▼|MS180.85-3.12 (-1.70%) ▼|MSFT524.59+3.51 (+0.67%) ▲|MU883.15+26.66 (+3.11%) ▲|NEE81.71-0.19 (-0.23%) ▼|NFLX66.12-0.93 (-1.39%) ▼|NKE37.48-0.85 (-2.21%) ▼|NOW158.45+1.45 (+0.92%) ▲|NVDA211.67-0.54 (-0.25%) ▼|ORCL127.74+2.20 (+1.75%) ▲|PEP135.50-3.34 (-2.40%) ▼|PFE30.04-0.38 (-1.25%) ▼|PG161.31-3.19 (-1.94%) ▼|PLTR196.12-0.08 (-0.04%) ▼|PM199.53-2.21 (-1.10%) ▼|QCOM174.94+2.11 (+1.22%) ▲|RTX191.65-3.07 (-1.57%) ▼|SBUX100.70-1.21 (-1.19%) ▼|SCHW90.45-0.99 (-1.08%) ▼|SO92.91-0.92 (-0.98%) ▼|SPG210.98-1.06 (-0.50%) ▼|T21.23-1.52 (-6.66%) ▼|TMO670.40-6.14 (-0.91%) ▼|TMUS148.89-9.90 (-6.23%) ▼|TSLA372.06-2.52 (-0.67%) ▼|TXN284.60+5.10 (+1.82%) ▲|UBER67.21-1.87 (-2.70%) ▼|UNH417.92-7.07 (-1.66%) ▼|UNP294.02-4.07 (-1.37%) ▼|UPS101.29-0.23 (-0.23%) ▼|USB59.61-0.41 (-0.68%) ▼|V409.13-5.21 (-1.26%) ▼|VZ44.46-0.74 (-1.64%) ▼|WFC82.36-0.66 (-0.79%) ▼|WMT119.41-1.71 (-1.41%) ▼|XOM182.62+4.39 (+2.46%) ▲|AAPL347.68-0.55 (-0.16%) ▼|ABBV285.80+0.61 (+0.21%) ▲|ABT103.39+0.88 (+0.85%) ▲|ACN246.85-11.89 (-4.60%) ▼|ADBE265.46-5.09 (-1.88%) ▼|AMAT379.68+4.10 (+1.09%) ▲|AMD517.55+9.62 (+1.89%) ▲|AMGN440.79-6.50 (-1.45%) ▼|AMT188.31+6.74 (+3.71%) ▲|AMZN248.72-1.66 (-0.66%) ▼|AVGO324.44+1.20 (+0.37%) ▲|AXP313.19-11.99 (-3.69%) ▼|BA188.39+0.84 (+0.45%) ▲|BAC50.69-0.39 (-0.76%) ▼|BKNG157.14-3.96 (-2.46%) ▼|BLK1,113.83-23.46 (-2.06%) ▼|BMY61.60-1.41 (-2.23%) ▼|BNY145.18-0.14 (-0.10%) ▼|BRK-B541.26-5.72 (-1.04%) ▼|C120.98-1.53 (-1.25%) ▼|CAT687.03-17.02 (-2.42%) ▼|CL93.96-3.44 (-3.53%) ▼|CMCSA22.79-0.06 (-0.24%) ▼|COF200.41-3.03 (-1.49%) ▼|COP151.55+5.92 (+4.06%) ▲|COST1,005.69-12.53 (-1.23%) ▼|CRM248.53-1.76 (-0.70%) ▼|CSCO106.27+1.38 (+1.31%) ▲|CVS93.49-0.99 (-1.05%) ▼|CVX232.73+6.05 (+2.67%) ▲|DE644.45+0.83 (+0.13%) ▲|DHR227.11-2.64 (-1.15%) ▼|DIS112.83-0.30 (-0.27%) ▼|DUK124.62-0.78 (-0.62%) ▼|EMR162.15+1.86 (+1.16%) ▲|FDX299.08-4.84 (-1.59%) ▼|GD350.40-0.39 (-0.11%) ▼|GE287.94-5.60 (-1.91%) ▼|GEV825.89-1.53 (-0.18%) ▼|GILD156.61-0.58 (-0.37%) ▼|GM75.84-1.38 (-1.78%) ▼|GOOG319.00-1.76 (-0.55%) ▼|GOOGL322.04-2.18 (-0.67%) ▼|GS882.67-8.63 (-0.97%) ▼|HD318.43-9.30 (-2.84%) ▼|HON221.41+3.10 (+1.42%) ▲|IBM252.93+0.82 (+0.33%) ▲|INTC86.84+1.35 (+1.57%) ▲|INTU346.15-8.75 (-2.47%) ▼|ISRG453.48+9.63 (+2.17%) ▲|JNJ263.03-4.59 (-1.71%) ▼|JPM332.14-4.41 (-1.31%) ▼|KO92.81-2.54 (-2.66%) ▼|LIN508.28-2.08 (-0.41%) ▼|LLY1,264.74-41.96 (-3.21%) ▼|LMT606.54+16.63 (+2.82%) ▲|LOW198.74-5.63 (-2.75%) ▼|LRCX230.80+0.65 (+0.28%) ▲|MA622.06-11.15 (-1.76%) ▼|MCD247.61-5.02 (-1.99%) ▼|MDLZ63.54-1.65 (-2.53%) ▼|MDT95.87-0.72 (-0.75%) ▼|META644.58-4.28 (-0.66%) ▼|MMM173.96-1.61 (-0.91%) ▼|MO74.46-1.61 (-2.12%) ▼|MRK145.00-2.24 (-1.52%) ▼|MS180.85-3.12 (-1.70%) ▼|MSFT524.59+3.51 (+0.67%) ▲|MU883.15+26.66 (+3.11%) ▲|NEE81.71-0.19 (-0.23%) ▼|NFLX66.12-0.93 (-1.39%) ▼|NKE37.48-0.85 (-2.21%) ▼|NOW158.45+1.45 (+0.92%) ▲|NVDA211.67-0.54 (-0.25%) ▼|ORCL127.74+2.20 (+1.75%) ▲|PEP135.50-3.34 (-2.40%) ▼|PFE30.04-0.38 (-1.25%) ▼|PG161.31-3.19 (-1.94%) ▼|PLTR196.12-0.08 (-0.04%) ▼|PM199.53-2.21 (-1.10%) ▼|QCOM174.94+2.11 (+1.22%) ▲|RTX191.65-3.07 (-1.57%) ▼|SBUX100.70-1.21 (-1.19%) ▼|SCHW90.45-0.99 (-1.08%) ▼|SO92.91-0.92 (-0.98%) ▼|SPG210.98-1.06 (-0.50%) ▼|T21.23-1.52 (-6.66%) ▼|TMO670.40-6.14 (-0.91%) ▼|TMUS148.89-9.90 (-6.23%) ▼|TSLA372.06-2.52 (-0.67%) ▼|TXN284.60+5.10 (+1.82%) ▲|UBER67.21-1.87 (-2.70%) ▼|UNH417.92-7.07 (-1.66%) ▼|UNP294.02-4.07 (-1.37%) ▼|UPS101.29-0.23 (-0.23%) ▼|USB59.61-0.41 (-0.68%) ▼|V409.13-5.21 (-1.26%) ▼|VZ44.46-0.74 (-1.64%) ▼|WFC82.36-0.66 (-0.79%) ▼|WMT119.41-1.71 (-1.41%) ▼|XOM182.62+4.39 (+2.46%) ▲|
15.7 C
New York
Friday, October 23, 2026

Tag: pharmaceuticals

newsFORsourcecompanycontentinformation1releasesmarket

Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity

HYDERABAD, India, August 1, 2025 /PRNewswire/ -- Zenara Pharma Private Limited ("Zenara"), a Biophore company, today announced that it has received final approval from the U.S....

Diplomatic Trade Ltd, Thomas J. Kent Jr. the Kent Family Office, and Kent Global LLC Stake Acquisition in Turkish Pharma Firm, Target $300M UAE...

Cross-border biopharma venture targets $300M IPO valuation and UAE facility launch by Q3 2025

Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity

HYDERABAD, India, July 31, 2025 /PRNewswire/ -- Zenara Pharma Private Limited ("Zenara"), a Biophore company, today announced that it has received final approval from the U.S....

Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and...

The treatment-resistant hypertension (TRH) market is expected to grow in the coming years due to the rising prevalence of uncontrolled hypertension and associated cardiovascular...

Indovinya unveils new brand positioning inspired by the transformative power of chemistry

The global specialty chemicals and surfactants company strengthens its brand, driving innovation and sustainability SÃO PAULO, July 31, 2025 /PRNewswire/ -- Indovinya, the specialty chemicals...

ADR Ratio Change Effective

July 31, 2025

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Agios Pharmaceuticals today announced financial results and updates for the second quarter ended June 30, 2025.

Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range


Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

GreenPower Provides Business Update and Reports Year-End Fiscal 2025 Results

Webinar Scheduled for August 4, 2025 at 4:15 p.m. EST/1:15 p.m. PST VANCOUVER, BC, July 30, 2025 /CNW/ -- GreenPower Motor Company Inc. (Nasdaq: GP)...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, August 6, 2025, to report its second quarter 2025 financial results and provide a corporate update.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceuticals

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers